Press Releases

Date Title and Summary Additional Formats
Toggle Summary Minerva Neurosciences Announces Findings Showing Effect of Roluperidone on Brain-Derived Neurotrophic Factor (BDNF)
WALTHAM, Mass. , Aug. 22, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced findings from a recent pre-clinical study that provide
View HTML
Toggle Summary Minerva Neurosciences Reports Second Quarter 2018 Financial Results and Business Updates
Five ongoing late-stage trials on track for data readouts in 2019 WALTHAM, Mass. , Aug. 02, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today
View HTML
Toggle Summary Minerva Neurosciences to Report Second Quarter 2018 Financial Results and Business Updates on August 2, 2018
Management to host conference call WALTHAM, Mass. , July 26, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it will release
View HTML
Toggle Summary Minerva Neurosciences Names Devin Smith Senior Vice President, General Counsel
WALTHAM, Mass. , July 25, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced the appointment of Devin W.
View HTML
Toggle Summary Minerva Neurosciences Elects Jeryl Hilleman to Board of Directors
WALTHAM, Mass. , July 17, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced the election of Jeryl Hilleman to the Board of Directors
View HTML
Toggle Summary Minerva Neurosciences to Present at Jefferies 2018 Global Healthcare Conference on June 6, 2018
WALTHAM, Mass. , May 30, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat central nervous system (CNS) disorders, today announced that it will present at the Jefferies 2018
View HTML
Toggle Summary Journal of Clinical Psychiatry Publishes Positive Results of Cognitive Performance From Phase 2B Trial of Roluperidone, Under Development by Minerva Neurosciences for the Treatment of Negative Symptoms in Schizophrenia
WALTHAM, Mass. , May 17, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders (CNS), today announced that The Journal of Clinical Psychiatry has published
View HTML
Toggle Summary Minerva Neurosciences Reports First Quarter 2018 Financial Results and Business Updates
WALTHAM, Mass. , May 03, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today reported key business updates and financial results for the quarter
View HTML
Toggle Summary Minerva Neurosciences to Report First Quarter 2018 Financial Results and Business Updates on May 3, 2018
Management to host conference call WALTHAM, Mass. , April 26, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it will release
View HTML
Toggle Summary Minerva Neurosciences Screens First Patient in Phase 2b Trial of MIN-117 to Treat Major Depressive Disorder
Multi-center trial to enroll approximately 324 patients at approximately 40 clinical sites in U.S. and Europe WALTHAM, Mass. , April 09, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat
View HTML